Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: Molecular genetic dissection of non-REM and REM sleep regulatory processes

Neuron

Volumn 38, Issue 5, 2003, Pages 715-730

  Willie, Jon T ^a,b   Chemelli, Richard M ^a,b   Sinton, Christopher M ^a   Tokita, Shigeru ^a,b   Williams, S Clay ^a,b   Kisanuki, Yaz Y ^a,b   Marcus, Jacob N ^c   Lee, Charlotte ^c,d   Elmquist, Joel K ^c,d   Kohlmeier, Kristi A ^e   Leonard, Christopher S ^e   Richardson, James A ^a   Hammer, Robert E ^a,b   Yanagisawa, Masashi ^a,b,f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OREXIN; OREXIN 2 RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN DYSFUNCTION; BRAIN NERVE CELL; CATAPLEXY; CONTROLLED STUDY; ELECTROPHYSIOLOGY; EMBRYO; HYPOTHALAMUS; MEDICAL DOCUMENTATION; MOLECULAR GENETICS; MOUSE; NARCOLEPSY; NONHUMAN; NONREM SLEEP; PRIORITY JOURNAL; REGULATORY MECHANISM; REM SLEEP; SIGNAL TRANSDUCTION; WAKEFULNESS;

EID: 0038724250     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(03)00330-1     Document Type: Article

References (63)

1. Aldrich M.S. Diagnostic aspects of narcolepsy. Neurology. 50:1998;S2-S7.
2. Alloway C.E., Ogilvie R.D., Shapiro C.M. EEG spectral analysis of the sleep-onset period in narcoleptics and normal sleepers. Sleep. 22:1999;191-203.
3. Baker T.L., Foutz A.S., McNerney V., Mitler M.M., Dement W.C. Canine model of narcolepsy. genetic and developmental determinants Exp. Neurol. 75:1982;729-742.
4. Bayer L., Eggermann E., Serafin M., Saint-Mleux B., Machard D., Jones B., Muhlethaler M. Orexins (hypocretins) directly excite tuberomammillary neurons. Eur. J. Neurosci. 14:2001;1571-1575.
5. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y.et al. Narcolepsy in orexin knockout mice. molecular genetics of sleep regulation Cell. 98:1999;437-451.
6. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., Fukuhara C., Battenberg E.L., Gautvik V.T., Bartlett F.S. 2nd et al. The hypocretins. hypothalamus-specific peptides with neuroexcitatory activity Proc. Natl. Acad. Sci. USA. 95:1998;322-327.
7. Dement W., Rechtschaffen A., Gulevich G. The nature of the narcoleptic sleep attack. Neurology. 16:1966;18-33.
8. Dyken M.E., Yamada T., Lin-Dyken D.C., Seaba P. Narcolepsy. unequivocal diagnosis after split-screen, video-polysomnographic analysis of a prolonged cataplectic attack Neurology. 44:1994;760-761.
9. Dyken M.E., Yamada T., Lin-Dyken D.C., Seaba P., Yeh M. Diagnosing narcolepsy through the simultaneous clinical and electrophysiologic analysis of cataplexy. Arch. Neurol. 53:1996;456-460.
10. Elias C.F., Saper C.B., Maratos-Flier E., Tritos N.A., Lee C., Kelly J., Tatro J.B., Hoffman G.E., Ollmann M.M., Barsh G.S.et al. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J. Comp. Neurol. 402:1998;442-459.
11. Eriksson K.S., Sergeeva O., Brown R.E., Haas H.L. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J. Neurosci. 21:2001;9273-9279.
12. Eschalier A., Fialip J., Varoquaux O., Makambila M.C., Marty H., Bastide P. Pharmacokinetic patterns of repeated administration of antidepressants in animals. I. Implications for antinociceptive action of clomipramine in mice. J. Pharmacol. Exp. Ther. 245:1988;963-968.
13. Franklin K.B., Paxinos G. The Mouse Brain in Stereotaxic Coordinates. 1997;Academic Press, San Diego.
14. Guilleminault C., Wilson R.A., Dement W.C. A study on cataplexy. Arch. Neurol. 31:1974;255-261.
15. Guilleminault C., Billiard M., Montplaisir J., Dement W.C. Altered states of consciousness in disorders of daytime sleepiness. J. Neurol. Sci. 26:1975;377-393.
16. Hara J., Beuckmann C.T., Nambu T., Willie J.T., Chemelli R.M., Sinton C.M., Sugiyama F., Yagami K., Goto K., Yanagisawa M., Sakurai T. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 30:2001;345-354.
17. Hishikawa Y., Shimizu T. Physiology of REM sleep, cataplexy, and sleep paralysis. Adv. Neurol. 67:1995;245-271.
18. Honda Y. Clinical features of narcolepsy. Japanese experiences Honda T., Juji T. HLA in Narcolepsy. 1988;Springer-Verlag, Berlin. 24-57.pp.
19. Huang Z.L., Qu W.M., Li W.D., Mochizuki T., Eguchi N., Watanabe T., Urade Y., Hayaishi O. Arousal effect of orexin A depends on activation of the histaminergic system. Proc. Natl. Acad. Sci. USA. 98:2001;9965-9970.
20. Hungs M., Mignot E. Hypocretin/orexin, sleep and narcolepsy. Bioessays. 23:2001;397-408.
21. Hungs M., Fan J., Lin L., Lin X., Maki R.A., Mignot E. Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res. 11:2001;531-539.
22. Ishizuka T., Yamamoto Y., Yamatodani A. The effect of orexin-A and -B on the histamine release in the anterior hypothalamus in rats. Neurosci. Lett. 323:2002;93-96.
23. Jones B.E. The neural basis of consciousness across the sleep-waking cycle. Adv. Neurol. 77:1998;75-94.
24. Kanbayashi T., Inoue Y., Chiba S., Aizawa R., Saito Y., Tsukamoto H., Fujii Y., Nishino S., Shimizu T. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J. Sleep Res. 11:2002;91-93.
25. Kilduff T.S., Peyron C. The hypocretin/orexin ligand-receptor system. implications for sleep and sleep disorders Trends Neurosci. 23:2000;359-365.
26. Kitahama K., Valatx J.L. Instrumental and pharmacological paradoxical sleep deprivation in mice. strain differences Neuropharmacology. 19:1980;529-535.
27. Kiyashchenko L.I., Mileykovskiy B.Y., Maidment N., Lam H.A., Wu M.F., John J., Peever J., Siegel J.M. Release of hypocretin (orexin) during waking and sleep states. J. Neurosci. 22:2002;5282-5286.
28. Kushida C.A., Baker T.L., Dement W.C. Electroencephalographic correlates of cataplectic attacks in narcoleptic canines. Electroencephalogr. Clin. Neurophysiol. 61:1985;61-70.
29. Lin J.S., Hou Y., Sakai K., Jouvet M. Histaminergic descending inputs to the mesopontine tegmentum and their role in the control of cortical activation and wakefulness in the cat. J. Neurosci. 16:1996;1523-1537.
30. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., Qiu X., de Jong P.J., Nishino S., Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 98:1999;365-376.
31. Lucas E.A., Foutz A.S., Dement W.C., Mitler M.M. Sleep cycle organization in narcoleptic and normal dogs. Physiol. Behav. 23:1979;737-743.
32. Marcus J.N., Aschkenasi C.J., Lee C.E., Chemelli R.M., Saper C.B., Yanagisawa M., Elmquist J.K. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 435:2001;6-25.
33. McGinty D., Szymusiak R. Brain structures and mechanisms involved in the generation of NREM sleep. focus on the preoptic hypothalamus Sleep Med. Rev. 5:2001;323-342.
34. Mignot E., Lammers G.J., Ripley B., Okun M., Nevsimalova S., Overeem S., Vankova J., Black J., Harsh J., Bassetti C.et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59:2002;1553-1562. a.
35. Mignot E., Taheri S., Nishino S. Sleeping with the hypothalamus. emerging therapeutic targets for sleep disorders Nat. Neurosci. Suppl. 5:2002;1071-1075. b.
36. Mitler M.M., Dement W.C. Sleep studies on canine narcolepsy. pattern and cycle comparisons between affected and normal dogs Electroencephalogr. Clin. Neurophysiol. 43:1977;691-699.
37. Mondal M.S., Nakazato M., Date Y., Murakami N., Yanagisawa M., Matsukura S. Widespread distribution of orexin in rat brain and its regulation upon fasting. Biochem. Biophys. Res. Commun. 256:1999;495-499.
38. Nishino S., Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog. Neurobiol. 52:1997;27-78.
39. Nishino S., Riehl J., Hong J., Kwan M., Reid M., Mignot E. Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Neurosci. Res. 38:2000;437-446.
40. Nishino S., Fujiki N., Ripley B., Sakurai E., Kato M., Watanabe T., Mignot E., Yanai K. Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci. Lett. 313:2001;125-128.
41. Parmentier R., Ohtsu H., Djebbara-Hannas Z., Valatx J.L., Watanabe T., Lin J.S. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice. evidence for the role of brain histamine in behavioral and sleep-wake control J. Neurosci. 22:2002;7695-7711.
42. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18:1998;9996-10015.
43. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., Nevsimalova S., Aldrich M., Reynolds D., Albin R.et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6:2000;991-997.
44. Radulovacki M., Virus R.M., Djuricic-Nedelson M., Green R.D. Adenosine analogs and sleep in rats. J. Pharmacol. Exp. Ther. 228:1984;268-274.
45. Ripley B., Fujiki N., Okura M., Mignot E., Nishino S. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol. Dis. 8:2001;525-534. a.
46. Ripley B., Overeem S., Fujiki N., Nevsimalova S., Uchino M., Yesavage J., Di Monte D., Dohi K., Melberg A., Lammers G.J.et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology. 57:2001;2253-2258. b.
47. Roth B., Bruhova S., Lehovsky M. REM sleep and NREM sleep in narcolepsy and hypersomnia. Electroencephalogr. Clin. Neurophysiol. 26:1969;176-182.
48. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., Williams S.C., Richardson J.A., Kozlowski G.P., Wilson S.et al. Orexins and orexin receptors. a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior Cell. 92:1998;573-585.
49. Saper C.B., Chou T.C., Scammell T.E. The sleep switch. hypothalamic control of sleep and wakefulness Trends Neurosci. 24:2001;726-731.
50. Sherin J.E., Elmquist J.K., Torrealba F., Saper C.B. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J. Neurosci. 18:1998;4705-4721.
51. Shneerson J.M. Handbook of Sleep Medicine. 2000;Blackwell Science Ltd, Oxford.
52. Smith M.I., Piper D.C., Duxon M.S., Upton N. Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci. Lett. 341:2003;256-258.
53. Steriade M., McCarley R.W. Brainstem Control of Wakefulness and Sleep. 1990;Plenum, New York.
54. Sutcliffe J.G., de Lecea L. The hypocretins. setting the arousal threshold Nat. Rev. Neurosci. 3:2002;339-349.
55. Tafti M., Franken P., Kitahama K., Malafosse A., Jouvet M., Valatx J.L. Localization of candidate genomic regions influencing paradoxical sleep in mice. Neuroreport. 8:1997;3755-3758.
56. Taheri S., Zeitzer J.M., Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu. Rev. Neurosci. 25:2002;283-313.
57. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., Cornford M., Siegel J.M. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 27:2000;469-474.
58. Willie J.T., Chemelli R.M., Sinton C.M., Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu. Rev. Neurosci. 24:2001;429-458.
59. Wisor J.P., Nishino S., Sora I., Uhl G.H., Mignot E., Edgar D.M. Dopaminergic role in stimulant-induced wakefulness. J. Neurosci. 21:2001;1787-1794.
60. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., Hollenberg A.N., Baggio L., Saper C.B., Drucker D.J., Elmquist J.K. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 110:2002;43-52.
61. Yamanaka A., Tsujino N., Funahashi H., Honda K., Guan J.L., Wang Q.P., Tominaga M., Goto K., Shioda S., Sakurai T. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem. Biophys. Res. Commun. 290:2002;1237-1245.
62. Yoshida Y., Fujiki N., Nakajima T., Ripley B., Matsumura H., Yoneda H., Mignot E., Nishino S. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur. J. Neurosci. 14:2001;1075-1081.
63. Zorick F.J., Salis P.J., Roth T., Kramer M. Narcolepsy and automatic behavior. a case report J. Clin. Psychiatry. 40:1979;194-197.